0000000000199160

AUTHOR

Claus Belka

showing 3 related works from this author

No evidence for sequences structurally related to the RB1 gene in the human genome.

1991

The retinoblastoma (RB1) gene is a ubiquitously expressed gene encoding a cell-cycle control protein. Inactivation of this gene plays a crucial role in the development of retinoblastoma, osteosarcoma, and other tumors. In a search for structurally related gene sequences we identified a 5.5-kb BamHI fragment strongly cross-hybridizing with the 5′ end of the RB1 cDNA. Molecular cloning, in situ hybridization, restriction mapping, and sequence analysis identified this DNA segment as the 28S rRNA gene. The absence of other cross-hybridizing sequences suggests that the RB1 gene is not part of a structurally related gene family.

Therapeutic gene modulationGeneticsBase SequenceGenome HumanMolecular Sequence DataRestriction MappingPair-rule geneGene targetingBiologyDNA Ribosomaleye diseasesGene productBlotting SouthernGene mappingSequence Homology Nucleic AcidGene clusterRNA Ribosomal 28SGeneticsGene familyHumansGenes RetinoblastomaGenetics (clinical)Regulator geneHuman genetics
researchProduct

LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced…

2014

4081 Background: Patients (pts) with LAEC have a poor prognosis; new therapies are required. A study showed the addition of Cet to RCT to be safe and effective for resectable EC [Ruhstaller et al, ...

CisplatinOncologyCancer ResearchPoor prognosismedicine.medical_specialtyCetuximabbusiness.industryLocally advancedPhases of clinical researchEsophageal cancermedicine.diseaselaw.inventionOncologyRandomized controlled triallawInternal medicinemedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Smal…

2015

Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction. Patients and Methods Patients with pathologically proven IIIA(N2) and selected patients with IIIB disease that had medical/functional operability received induction chemotherapy, which consisted of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 ev…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentMedizinPhases of clinical researchVinblastineVinorelbineDrug Administration SchedulePneumonectomyCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPneumonectomyLung cancerAgedNeoplasm Stagingbusiness.industryDose fractionationInduction chemotherapyVinorelbineChemoradiotherapyInduction ChemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyFemaleDose Fractionation RadiationCisplatinbusinessChemoradiotherapymedicine.drugJournal of Clinical Oncology
researchProduct